Product Type
Antibody
Description
The monoclonal antibody aE11 reacts with the C9 neoantigen of the terminal complement complex (TCC). Three different activation pathways of complement are fused with the formation of C5 convertase. The cleavage of C5 by this invertase initiates the cleavage or terminal pathway. In contrast to activation pathways that require enzymatic cleavage, the terminal pathway relies on binding-induced conformational changes. The binding of C6 promotes the binding of C7, which changes the conformation of the complex. After C8 is bound, a variable number of C9 molecules associate with the C5b678 complex, which is also called the terminal complement complex (TCC). The formation of TCC causes cell lysis or can trigger a variety of cellular metabolic pathways, leading to the synthesis and release of inflammatory mediators. TCC contains neoantigens that are not present in a single natural component. -C9 neoantigen exists in both membrane-bound (MAC) and liquid phase (SC5b-9) complexes. TCC exists in normal human plasma and increases in patients with complement activation.
Disease
Infectious diseases, Nephrology
Size
100 µg
Immunogen
C3b(i)-Sepharose
Species
Human
Cross reactivity
Horse, Pig
Clonality
Monoclonal
Clone Number
aE11
Buffer
PBS with a concentration of at least 10 mg/ml. The endotoxin concentration is < 24 EU/mg, determined with LAL Assay.
Application
Flow cytometry, Frozen sections, Functional studies, Immuno assays, Immuno fluorescence, Paraffin sections
Application Notes
The diluent used depends on the detection system used. It is recommended that users test reagents and determine their own optimal dilution. The typical initial working dilution is 1:50.
Storage Instructions
Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year.
Alternative Names
Terminal complement complex; MAC complex; complement membrane attack complex; sC5b-9 complex.
